Effects of vitamin D3 adjuvant therapy on pulmonary function and airway inflammation in children with bronchial asthma / 中国基层医药

ABSTRACT

Objective:To investigate the effects of vitamin D3 adjuvant therapy on pulmonary function and airway inflammation in children with bronchial asthma, providing evidence for clinical treatment of bronchial asthma.Methods:100 children with bronchial asthma who received treatment in Xin'an International Hospital from January 2018 to June 2020 were included in this study. They were randomly assigned to receive either conventional treatments (such as bronchodilator and glucocorticoid treatments)(control group, n = 50) or conventional treatment combined with vitamin D3 adjuvant treatment (observation group, n = 50) for 9 days. Clinical efficacy and adverse reactions were compared between the two groups. Before and after treatment, forced expiratory volume in 1 second (FEV 1), forced vital capacity (FVC), tumor necrosis factor-alpha (TNF-α), interleukin 10 (IL-10), and interleukin-5 (IL-5) levels were compared between the two groups. Results:Total effective rate in the observation group was significantly higher than that in the control group [94.00% (47/50) vs. 80.00% (40/50), χ2 = 4.332, P < 0.05]. After treatment, FEV 1 and FVC levels in each group were significantly increased compared with before treatment (both P < 0.05). After treatment, FEV 1 and FVC levels in the observation group were (1.47 ± 0.42) L and (2.09 ± 0.64) L, respectively, which were significantly higher than those in the control group [(1.21 ± 0.34) L, (1.85 ± 0.47) L, t = 2.137, 3.402, both P < 0.05]. After treatment, TNF-α and IL-5 levels in each group were significantly deceased (both P < 0.001), and IL-10 level was significantly increased ( P < 0.001), compared with before treatment in the same group. After treatment, TNF-α and IL-5 levels in the observation group were (0.58 ± 0.13) ng/L and (39.37 ± 3.54) ng/L, respectively, which were significantly lower than those in the control group [(0.92 ± 0.23) ng/L, (61.36 ± 5.72) ng/L], t = 9.099, 38.628, both P < 0.001]. After treatment, IL-10 level in the observation group was significantly higher than that in the control group [(215.62 ± 13.25) ng /L vs. (127.28 ± 9.27) ng/L, t = 23.115, P < 0.001]. Conclusion:Vitamin D3 adjuvant therapy for the treatment of bronchial asthma in children can help promote pulmonary function recovery and reduce airway inflammation, which is worthy of clinical application.